An Intracranial Bleed, a Warfarin Patient, and a Pharmacy That Doesn't Stock the Right Reversal Agent
The guideline answer for reversing his warfarin is not actually in question — what's in question is whether a small rural hospital's pharmacy can produce it fast enough to matter.
W.H., a 74-year-old man, was brought to his small rural hospital's emergency department after his wife found him confused and slurring his words while she was reheating the dinner he'd left half-finished at the table, and a CT scan showed an acute intracranial hemorrhage with a repeat scan twenty minutes later already showing early expansion. He takes warfarin for atrial fibrillation, and his INR today is 3.8 — supratherapeutic, and the direct explanation for why a hemorrhage that might otherwise have stayed small is actively growing while the team tries to reverse it. Every major guideline addressing this exact situation, emergent life-threatening bleeding on a vitamin K antagonist, recommends four-factor prothrombin complex concentrate over fresh frozen plasma, on the strength of Sarode's randomized comparison, which found faster INR correction and more effective hemostasis with meaningfully less volume — a real, specific advantage for a patient whose brain cannot tolerate more time or more intracranial pressure than it already has.
The problem is not clinical uncertainty; it is his hospital's pharmacy, which does not stock 4-factor PCC — a genuine cost and low-demand-inventory issue at a facility this size, not an oversight anyone there considers correctable tonight. Fresh frozen plasma is on hand and can be thawed, but thawing takes roughly twenty to thirty minutes even on an expedited protocol, and the volume required to meaningfully correct his INR is substantial for a 74-year-old whose cardiac history includes a prior heart failure admission, raising a real risk of volume overload on top of an already expanding bleed. Transfer to a tertiary center that stocks 4-factor PCC would take at least forty-five minutes by ground given tonight's weather, time the guideline-preferred agent doesn't need but the actual hospital in front of them cannot make appear.
His wife, still in the room, has already been told plainly that no option available tonight is without real risk, and that the team's job is choosing the least bad path forward rather than a clean one — a framing the emergency physician offers deliberately, having seen families interpret any hedge in a clinician's voice as a sign something is being withheld rather than as an honest description of a genuinely difficult night.
In the ED, twenty minutes after the repeat CT
His hematoma is already expanding on a scan twenty minutes old. Transfer alone costs forty-five minutes tonight, plus whatever time it takes to actually administer PCC once he arrives — that's close to an hour of continued expansion while the guideline-preferred drug sits in a building we can't reach fast enough. I'd start FFP here, now, with vitamin K, because sooner beats better when the clock is the variable that matters most.
I don't disagree that time matters, but FFP's volume load is a real, separate risk for him specifically — he has reduced cardiac reserve from a prior heart failure admission, and the volume needed to meaningfully correct an INR of 3.8 with plasma is substantial. We could stop the bleeding's cause and start a second complication in the same hour.
Sarode's trial wasn't a marginal finding — faster correction and less volume, in exactly this kind of patient.
I don't think we have to choose one path exclusively tonight. Start FFP now, at reduced initial volume with close monitoring given his cardiac history, alongside vitamin K — and simultaneously call the tertiary center to begin transfer arrangements in parallel, not as a fallback we only consider if FFP fails, but as something already moving while we watch how he responds.
If his bleeding or hemodynamics don't stabilize with what we can do here, the transfer and 4-factor PCC are already in motion rather than just being requested at that later point — that's the version of this decision that doesn't force us to bet everything on either option alone.
Agreed: FFP started immediately at reduced initial volume with vitamin K, cardiac status monitored closely, and transfer to the tertiary center for 4-factor PCC arranged in parallel rather than held as a contingency. Repeat CT planned at one hour to assess whether local measures are controlling expansion.